Genomics-guided precision medicine for metastatic breast cancer

Comprehensive Assessment of Clinical Features and Biomarkers to Identify Patients With Advanced or Metastatic Breast Cancer for Marker Driven Trials in Humans (CATCH)

This study is testing whether using genetic information from tumors and blood samples can help doctors create personalized treatment plans for people with metastatic breast cancer.

Quick facts

• Study type: Observational
• Enrollment: 5000 (estimated)
• Ages: 14 Years to 100 Years
• Sex: All
• Sponsor: German Cancer Research Center (other)
• Locations: 12 sites (Augsburg and 11 other locations)
• Trial ID: NCT05652569 on ClinicalTrials.gov

What this trial studies

CATCH is an observational study that aims to implement genomics-guided precision medicine for patients with metastatic breast cancer. It involves collecting tumor and blood samples from patients at the time of diagnosis or disease progression to conduct genomic and transcriptomic profiling. This profiling helps identify biomarkers and potential drug targets, guiding personalized therapeutic interventions. The study seeks to integrate these precision oncology workflows into clinical practice to improve treatment outcomes.

Who should consider this trial

Good fit: Ideal candidates for this study are adults with advanced or metastatic breast cancer, regardless of gender or molecular subtype.

Not a fit: Patients with early-stage breast cancer or those unable to provide a tissue biopsy may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more effective, personalized treatment options for patients with metastatic breast cancer.

How similar studies have performed: Other studies have shown promise in using genomics-guided approaches for cancer treatment, indicating that this method has potential for success.

Eligibility criteria

Inclusion Criteria:

* Female and male breast cancer patients ≥ 18 or if the legal guardian has agreed to the respective informed consent form (ICF)
* Patients with advanced or metastatic breast cancer (irrespective of clinical parameters such as TNM, subgroups, therapy lines)
* Patients, who agreed to and were able to sign the informed consent form.

Exclusion Criteria:

* Early breast cancer
* Inability to take a tissue bioptic sample due to reasons such as physical location of the lesion or health of the patient
* Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.

Where this trial is running

Augsburg and 11 other locations

• University Hospital Augsburg — Augsburg, Germany (RECRUITING)
• Charité — Berlin, Germany (RECRUITING)
• University Hospital Köln — Cologne, Germany (RECRUITING)
• Medical Faculty and University Hospital Carl Gustav Carus — Dresden, Germany (RECRUITING)
• University Hospital Erlangen — Erlangen, Germany (RECRUITING)
• University Hospital Essen — Essen, Germany (RECRUITING)
• National Center for Tumor Diseases — Heidelberg, Germany (RECRUITING)
• Caritas Hospital St. Josef — Regensburg, Germany (RECRUITING)
• Robert-Bosch-Krankenhaus Stuttgart — Stuttgart, Germany (RECRUITING)
• University Hospital Tübingen — Tübingen, Germany (RECRUITING)
• University Hospital Ulm — Ulm, Germany (RECRUITING)
• University Hospital Würzburg — Würzburg, Germany (RECRUITING)

Study contacts

• Principal investigator: Andreas Schneeweiss, MD — National Center for Tumor Diseases, Heidelberg
• Study coordinator: Andreas Schneeweiss, MD

Conditions: Metastatic Breast Cancer, Stage IV Breast Cancer, Precision Oncology, Genomics-Guided Biomarker-Stratification, Personalized Oncology, Genomic Profiling